Fisher Kerry, Hazini Ahmet, Seymour Leonard W
Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Cancers (Basel). 2021 Feb 10;13(4):719. doi: 10.3390/cancers13040719.
Dysregulation of HLA (human leukocyte antigen) function is increasingly recognized as a common escape mechanism for cancers subject to the pressures exerted by immunosurveillance or immunotherapeutic interventions. Oncolytic viruses have the potential to counter this resistance by upregulating HLA expression or encouraging an HLA-independent immunological responses. However, to achieve the best therapeutic outcomes, a prospective understanding of the HLA phenotype of cancer patients is required to match them to the characteristics of different oncolytic strategies. Here, we consider the spectrum of immune competence observed in clinical disease and discuss how it can be best addressed using this novel and powerful treatment approach.
HLA（人类白细胞抗原）功能失调日益被视为癌症在免疫监视或免疫治疗干预压力下常见的逃逸机制。溶瘤病毒有潜力通过上调HLA表达或促进不依赖HLA的免疫反应来对抗这种抗性。然而，为了实现最佳治疗效果，需要对癌症患者的HLA表型有前瞻性了解，以便将他们与不同溶瘤策略的特点相匹配。在此，我们考虑临床疾病中观察到的免疫能力范围，并讨论如何使用这种新颖且强大的治疗方法来最好地应对这一问题。
